Leukemia stem cells considered responsible for drug resistance and relapse of CML are especially resistant to TKI therapy, despite effective inhibition of BCR-ABL tyrosine kinase activity13. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.